Nyunt, Myaing

Public Health - International Health

Antimalarial treatment efficacy of artemether-lumefantrine in HIV-infected pregnant women.

Artemether-lumefantrine is the leading drug recommended by the World Health Organization (WHO) for the treatment of uncomplicated malaria. High treatment efficacy, good tolerability, and an acceptable safety profile of artemether-lumefantrine have been established in non-pregnant adults and children. However, despite increasing use of the drug in pregnant women in many endemic countries following the WHO recommendation, knowledge on the safety and efficacy of artemether-lumefantrine is extremely limited in pregnant women, especially in those living with HIV, who carry the highest burden of malaria-HIV co-infection. Available data suggest that pregnancy- and HIV-related immune suppression and suboptimal pharmacokinetics secondary to pregnancy-induced acceleration in drug disposition may hamper the efficacy and safety of artemether-lumefantrine. In collaboration with our colleagues in Mali, we propose to conduct a prospective clinical study to assess the efficacy and safety of artemether-lumefantrine in HIV-infected pregnant women. Thirty-five women with microscopy-proven uncomplicated falciparum malaria will be treated with the standard 6-doses of artemether-lumefantrine. Parasitemia will be monitored daily for 3 days and weekly for 6 weeks. The primary endpoint is the adequate clinical and parasitologic response determined at 42 days after the initiation of treatment. Safety monitoring will include both clinical and laboratory evaluation. The study findings will serve as preliminary data for a larger clinical trial to evaluate the relative contribution of acquired immunity, drug pharmacokinetics and drug resistance in antimalarial treatment outcomes of artemether-lumefantrine in HIV-infected pregnant women for which a clinical trial planning grant (R34) has been recently submitted to NIAID.

Craig W. Hendrix, M.D.; JH School of Medicine, Medicine, Div. of Clinical Pharmacology

People

Noreen Hynes, MD MPH

Director, Geographic Medicine Center of the Division of Infectious Diseases

Joanne Katz, ScD MS,BSc

Associate Chair, Director of Academic Programs

Stefan Baral, MD MPH,MBA,MSc

Director, Key Populations Program

Yukari C. Manabe, MD

Associate Director of Global Health Research and Innovation

Caitlin Kennedy, PhD MPH,BA

Co-Director, MPH concentration in Social and Behavioral Sciences in Public Health; Associate Director, Center for Qualitative...

Robert Bollinger Jr., MD MPH

Director, Johns Hopkins Center for Clinical Global Health Education (CCGHE); Associate Director, Johns Hopkins Center for Global...
«

May 2018

»
S
M
T
W
T
F
S
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·

Projects

Building an Enabling Environment for Vaccines in India...

This project, now in its second phase, aims to create an enabling environment for vaccines in India and contribute to...

Read More

Nutrition Innovation Lab

"Poshan", which means good nutrition in Nepali is ongoing research that involves two interlinked large-scale research studies...

Read More

Mpilonhle

Mpilonhle brings multi-dimensional services to adolescents in rural South Africa. Its objective is to reduce the very high...

Read More

Identification and Enumeration of Pathogens in Drinking...

CWH researchers are using polymerase chain reaction and mass spectrometry technologies to develop a microbial isolation and...

Read More